»Menu«

CV

pdf icon Click to Download Latest CV

Venuturupalli, Swamy, R, M.D

 

BUSINESS

8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048

Phone (310) 659 9959

E-mail : swamy@drswamy.com

Website : drswamy.com

 

EDUCATION

Topiwala National Medical College, Mumbai, India (1989-1995)

MB, BS (Bachelor of Medicine and Surgery)

  • Distinction in physiology
INTERNSHIP

SUNY Upstate Medical University, Syracuse, NY (1995-1996)                          

Intern - Department of Medicine

  • Program Director: David Heisig, M.D.
RESIDENCY

SUNY Upstate Medical University, Syracuse, NY (1996-1998)                            

Resident - Department of Medicine

  • Program Director: David Heisig, M.D.

SUNY Upstate Medical University, Syracuse, NY (1998-1999)                          

Chief Resident - Department of Medicine.

  • Program Director: David Heisig, M.D.
FELLOWSHIP

VA Greater Los Angeles and UCLA, Los Angeles, CA (1999-2000)                        

Ambulatory Care Fellowship in Health Services Research

  • Program Director: Paul Shekelle, M.D.,PhD.

UCLA- San Fernando Valley Program, Sepulveda, CA (2000-2002)

Rheumatology Fellowship

  • Program Director: Richard Weisbart, M.D.

LICENSURE

 

State of California Medical License: # A69893 (1999-present)

State of Indiana Medical License: # 01048571A (1999-2003)

BOARD CERTIFICATION

 

1998-2008:         American Board of Internal Medicine-certified in Internal Medicine.

2002-2022:        American Board of Internal Medicine-certified in Rheumatology.

2011-2021:        American Board of Internal Medicine-recertified in Internal Medicine.

PROFESSIONAL EXPERIENCE

PRESENT POSITION

Attending Physician

RS Venuturupalli, M.D., Inc., Private Practice, Rheumatology (2006-present)

Associate Clinical Professor of Medicine

David Geffen School of Medicine at UCLA (2012-present)

Clinical Investigator

“Wallace Rheumatic Diseases Center” and “Cedars Sinai Rheumatology Clinical Trials Center.” (2002-present)

Co-Chairman

Medical Advisory Board, Lupus LA (2014-present)

Attending Physician

Cedars Sinai Medical Center (2002-present)

PREVIOUS POSITIONS HELD

Clinical Chief, Division of Rheumatology

Cedars Sinai Medical Center (2011-2015)

Attending Physician

Allan L Metzger M.D., Inc., Private Practice, Rheumatology (2002-2006)

Assistant Clinical Professor of Medicine

David Geffen School of Medicine at UCLA (2006-2012)

 

Editor-in-Chief - Current Rheumatology Reports

An international journal published by Bentham Science Publishers (2009-2013)

Attending Physician

UCLA Ronald Regan Medical Center (2008-2010)

Attending Physician

Olympia Medical Center (2003-2009)

Member of the governing board

The Olive View Foundation (2004-2010)

Clinical Investigator

Medvin Clinical Research (2011-2012)

Chief Resident, Internal Medicine Training Program

Upstate Medical University, Syracuse, NY (1998-1999)

Co-Chair, Resident Advisory Committee on Graduate Medical Education

Upstate Medical University, Syracuse, NY (1998-1999)

PROFESSIONAL ACTIVITIES

COMMITTEE SERVICE
  • Member - Annual Meeting planning Committee (2013-2015)

American College of Rheumatology Annual Scientific Meeting

  • Member: Abstract Selection committee for clinical medicine (2006)

Society Of General Internal Medicine 28th Annual Scientific Meeting, Los Angeles, CA

  • Member: “The Hanging committee” (editorial advisory committee) (1999-2001)

Western Journal of Medicine, UCLA, Los Angeles, CA

  • Member: Abstract selection committee

“Education Interventions” subcommittee

  • Member: Research committee (2004-present)

Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA

  • Member: Fellowship selection committee (2004-present)

Cedars Sinai Medical Center, Division of Rheumatology, Los Angeles, CA.

  • Member: Fellowship evaluation committee (2004-present)

Cedars Sinai Medical Center, Division of Rheumatology, Los Angeles, CA

  • Member: Performance Improvement Committee (2011-present)

Department of Medicine

  • Member: Health Information Committee (2010-present)
COMMUNITY SERVICE
  • Volunteer Teaching Faculty (2003-2005)

Los Angeles Free Clinic, West Hollywood, CA

  • Volunteer Teaching Faculty (2003-2005)

Venice Family Clinic, Los Angeles, CA

  • Lupus expert (2011-present)

WebMD lupus forum

PROFESSIONAL ASSOCIATIONS
  • Member: American College of Physicians (1996-2009)
  • Member: Society of General Internal Medicine (1999-2005)
  • Fellow Member: American College of Rheumatology (2002-present)
  • Program Chair: Southern California Rheumatology Society (2004-2006)
  • Secretary and Treasurer: Southern California Rheumatology Society (2006-2008)
  • President: Southern California Rheumatology Society (2008-2010)
  • SGIM 25TH Annual Scientific Meeting, Atlanta, GA (2002)
  • Member: Bone Center of Excellence (2011- 2013)

Cedars Sinai Medical Center

  • Member: Medical Advisory Board

Lupus LA

CONSULTING ACTIVITIES
  • Speakers Bureau: Benlysta program

Human Genome Sciences and Glaxo Smith Kline (2012-2013)

 

  • Rheumatology Consultant: Regional Rheumatology treatment forum

Amgen, Inc. (2008)

  • Rheumatology Consultant: Helped train company executives about rheumatoid arthritis and biological therapies

Amgen, Inc. (2005)

  • Rheumatology consultant: Helped train executives of this pharmaceutical corporation about rheumatoid arthritis

Bristol Myers Squibb, Inc. (2005)

  • Technical consultant: For the release of ‘Restasis-cyclosporine eyedrops’

Allergan Pharmaceuticals (2003)

  • Research consultant: ‘Acupuncture for Fibromyalgia: a randomized placebo controlled blinded trial’

Southern California University for Health Sciences, Whittier, CA (2001)

EDITORIAL SERVICES
  • Reviewer for Journal

Journal of Clinical Rheumatology (2002-2003)

 

  • Reviewer for Journal

Journal of General Internal Medicine (2002-2004)

  • Reviewer for Journal

Western Journal of Medicine (1999)

 

  • Reviewer for Journal

Current Rheumatology Reviews (2009-present)

HONORS AND SPECIAL AWARDS

 

RESEARCH GRANTS

 

  • The use of abatacept in lupus nephritis.

Principal investigator at Cedars Sinai Medical Center       

(NIH Grant # N01A115416) (2008-2012)

  • Rituxan in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis.

Co-investigator at Cedars Sinai Medical Center

(NIH Grant # N01-AR-4-2273) (2007-2010)

  • Tocilizumab in Myositis

Principle investigator at Cedars Sinai

RESEARCH PROJECTS AND FOCUS

RESEARCH FOCUS
  • Clinical trials in SLE, RA, Sjogren’s syndrome and inflammatory muscle disease.
  • Health information technology based interventions in chronic disease care.
PRINCIPAL INVESTIGATOR IN MULTI-CENTER TRIALS
ACTIVE TRIALS
  1. PREDICT trial: A phase 4, multicenter, Randomized, 52 week study to evaluate the routine assessment of patient index data (RAPID3) compared to the Clinical Disease Activity Index (CDAI) to prospectively predict treatment success at 52 weeks based on a treatment decision at week 12 in subjects with moderate to severe rheumatoid arthritis receiving Certolizumab Pegol (CZP) (2011-present)
  2. C2013-0302: A phase II study to evaluate the safety and tolerability of SAN-300 in patients with active Rheumatoid arthritis. (2013-present)
  3. Tocilizumab in Refractory DM and PM: A randomized controlled trial of tocilizumab for refractory Dermatomyositis and Polymyositis. (2014-present)
COMPLETED TRIALS
  1. A long term study of the safety of Rituxan in patients with rheumatoid arthritis after an inadequate response of previous anti-TNF therapy. (SUNSTONE) (2007-2013)
  2. ITN034AI: CTLA4-Ig in the treatment of Lupus Nephritis. Multi-center RCT of Abatacept in the treatment of lupus nephritis. Sponsored by the Immune Tolerance Network a subsidiary of NIH. (NIH Grant # N01A115416) (2008-2012)
  3. Rituxan in Myositis study: Served as co-Principal investigator at Cedars Sinai in an NIH sponsored study of the drug Rituxan for the treatment of inflammatory muscle disease. PI- Dr. Michael Weisman. (RIM Study). National PI: Chester Oddis. (NIH Grant # N01-AR-4-2273) (2007- 2010)
  4. ACTFIRST TRIAL: A randomized controlled trial of adalimumab versus tocilucimab in rheumatoid arthritis patients. (2011-2012)
  5. A phase 1b, randomized, double-blind, placebo-controlled, Multicenter study to evaluate safety of multiple-dose, Intravenously administered medi-545, a fully human antiinterferon-Alpha monoclonal antibody, in adult patients with Dermatomyositis or polymyositis. (2008)
CO-INVESTIGATOR IN DRUG RANDOMIZED, DOUBLE – BLIND COLLABORATIVE TRIALS: Sub-investigator in the following trials
ACTIVE TRIALSs
  • IMMU-115-04: Phase 1b Study of SC Milatuzumab in SLE. (2014-)
  • A phase IIb, Multi-center, randomized, double – blind, placebo – controlled, multidose, 24 – week study to evaluate the efficacy and safety off the atacicept, in subjects with systemic lupus erythematosus. (2014-)
  • Phase 2A of Tocilizumab in the treatment of Polymyalgia Rheumatica. 
  • SLICC (Systemic lupus erythematosus International Coordinating Committee) Registry for Atherosclerosis, (2003-present), Registry for central nervous system lupus, (2003-present)
  • BMS IM 101-167, A Phase IIIb, Multicenter, Randomized, Withdrawal study to evaluate the Immunogenicity and safety of Subcutaneously Administered Abatacept in Adults with Active Rheumatoid Arthritis, (2008-)
  • A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-Bä), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States, (2008-present)
  • A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease Who Participated in Study SL0007. Protocol UCB SL0008, (2008- present)
  • Lupus Clinical Trials Consortium, Inc., LCTC Lupus Data Registry, (2009-)
  • Cedars Sinai Medical Center, Cross Cultural Spanish Validation of Lupus Pro: A Patient Reported Outcome Measure for Lupus, (2009- present)
  • TEVA Pharma - A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients with Active Lupus Arthritis. PROTOCOL LA-LAQ-202, NCT01085084 (2010-present)
  • Study of Epratuzumab in systemic lupus erythematosus, NCT00383513, (2010-present)
  • Duke Autoimmunity Pregnancy Registry (DAP Registry), (2010-present)
  • Concurrent pilot studies in Giant cell arteritis and Takayasu’s arteritis to examine the safety, efficacy, and immunologic effects of abatacept (CTLA4-Ig) in large vessel vasculitis, (2010- present)
COMPLETED TRIALS
  • IDEC, 102-20/WAI17042, A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination with MTX in Subjects with Active Rheumatoid Arthritis Who have had an inadequate Response to MTX and Anti-TNFalpha Therapies (2003-2005)
  • Novartis,CCOX189A2335, A 13-Week, multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study of COX189 200mg in patients with rheumatoid arthritis using naproxen 500mg b.i.d. as comparator (2003-2004)
  • Prometheus, 03-MTX-02, Measurement of Methotrexate and Folate Polyglutamate Levels and MTHFR Polymorphisms in a Cross-Section of Rheumatoid Arthritis Patients to Assess Correlations of Toxicity and Efficacy (2003-2006)
  • Human Genome Science, LBRA01, A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to evaluate the safety, tolerability and Efficacy of LymphoStat-B™ (LSB) in subjects with RA (2004-2005)
  • Abbott,M02-537, A Multicenter continuation trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients with Moderate to Severely Active Psoriatic Arthritis (2003-2006)
  • Biorad, Collection of Prospective Samples for Investigational Studies of Bio-Rad BioPlex 2200 ANA Screen on the BioPlex 2200 (2004- 2006)
  • SLICC (Systemic lupus erythematosus International Coordinating Committee) Registry for Atherosclerosis, 2003-present, Registry for central nervous system lupus (2003-present)
  • Prometheus Imuran SLE: An Open Label Safety and Efficacy Trial of Imuran for Patients with Systemic Lupus Erythematosus (2004-2006)
  • Wyeth Research: Protocol 3140A1-200-WW: A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects with Active Rheumatoid Arthritis on a Background of Methotrexate (2004-2005)
  • LJP: Protocol 394-90-14: A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 100mg and 300mg of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease (2004-2007)
  • Scios: Protocol B007: A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Oral SCIO-469 in Subjects with Active Rheumatoid Arthritis Who are not Receiving DMARDS Other than Hydroxychloroquine (2004-2006)
  • Orphan Medical, Inc.: Protocol OMC-SXB-26: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (sodium oxybate) with Placebo for the Treatment of Fibromyalgia (2004-2005)
  • Amgen B cell: An exploratory study to characterize the variability in circulating B cell populations in subjects with systemic lupus erythematosus (SLE) (2004-2006)
  • A Phase IIB MultiCenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Glucocorticosteroids in the Treatment of Active SLE and the Prevention of Subsequent Lupus Flares, BMS (2005-2008)
  • A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with Moderate to Severe SLE, Genentech (2005- 2011)
  • A Multi national, Multi center, randomized, double blind, placebo controlled, multiple dose, four arm study to assess the efficacy, tolerability and safety, of three different doses of Edratide (TV-4710) Subcutaneous injections in SLE patients, TEVA (2005-2007)
  • A phase III, Randomized, Double blind, Placebo controlled, multi center study of Epratuzumab in patients with acute severe SLE Flares Excluding the Renal or Neurologic Systems, Immunomedics (2005-2006)
  • A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Systemic Lupus Erythematosus (SLE), Human Genome Sciences (2005-2007)
  • A Phase Ib, multi-centre, double-blind, placebo-controlled, dose-escalating, single dose study to assess the safety, pharmacokinetics and pharmacodynamcs of TACI-Fc5 when administered subcutaneously to patients with SLE, Serono (2005-2006)
  • A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 623 following multidose administration in subjects with SLE, Amgen (2005-2006)
  • A Phase 2 study to evaluate the safety, tolerability and activity of fontolizumab (HuZaf) in patients with active rheumatoid arthritis, Protocol ZAF-711, sponsored by Protein Design Labs, Inc (PDL) (2006-2007)
  • Phase 1 Single Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Administered Intravenously in Subjects with Rheumatoid Arthritis. Protocol 15001, Trubion (2004-)
  • A double-blind, randomized, placebo controlled, dose escalating, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more disease modifying anti-rheumatic drugs. Protocol Hx-CD20-403 Genmab (2005-2007)
  • A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of Ocrelizumab compared to placebo in patients with active Rheumatoid Arthritis continuing Methotrexate treatment. Protocol WA20494/ACT3985g, Genetech (2005-2007)
  • A Phase III, Multicenter, Open-Label, Continuation Trial of LymphoStat-B Antibody (Monoclonal Anti-BLys Antibody) in Subjects with Rheumatoid Arthritis (RA) who Completed the Phase II LBRA 01. Protocol LBRA99, Human Genome Sciences (2006-2010)
  • An Exploratory study to characterize biomarker assays in healthy subjects and in subjects with Rheumatoid Arthritis. Protocol 92005637, Amgen (2006-2007)
  • A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients Who Have Mild System Lupus Erythematosus (SLE) With Cutaneous Involvement. Protocol MI-CP126, MedImmune (2006-2008)
  • “A phase III, Randomized, double-blind, placebo controlled, Multicenter study to evaluate the efficacy and safety of Rituximab in subjects with ISN/RPS Class III or IV Lupus Nephritis”. Protocol LUNAR, Genentech (2006-2009)
  • A phase III, Randomized double-blind, placebo controlled, multicenter trial of Epratuzumab in patients with active systemic lupus erythematosus. Protocol IMMU-103003 Immunomedics (2005-2006)
  • A multicenter, open label, continuation trial of lymphostat B antibody (monoclonal Anti-Blys antibody) in subjects with systemic lupus erythematosus (SLE) who completed the phase 2 protocol LBSL02. Protocol LBSL9, Human Genome Sciences (2006-2009)
  • Genentech IFN 3958g, A Phase I, Randomized, Double-blind, Placebo-controlled, escalating single and multiple dose study of the safety, tolerability, and Pharmacokinetics of rhuMAb IFNalpha In adults with mildly active SLE (2007-2009)
  • UCB SL0006, An Open-Label Re-treatment Trial for Patients Previously Randomized into the SL0003 and SL0004, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studies of Epratuzumab in patients with SLE (2007-2010)
  • UCB SL0007, A Phase Iib, Randomized, Double Blind, Placebo controlled, dose and dose regimen-ranging study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus erythematosus patients with Active Disease (2008-2010)
  • Medimmune MPI-CP152, A Phase IB, Multicenter, Randomized, Double-blind, Placebo-controlled, dose escalation study with an open label extension to evaluate the safety and tolerability of multiple intravenous doses of MEDI-545, a fully human Anti-Interferon-Alpha Monoclonal Antibody , in patients with Systemic Lupus Erythematosus (2007-2009)
  • Human Genome Sciences C1056, A Phase 3, Multi-Center, Randomized, Double-Blind, placebo-controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-Blys Antibody, in Subjects with SLE (2007-2009)
  • Genentech WA 20499/ACT4071g Ocrelizumab, A Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the efficacy and safety of two doses of Ocrelizumab in patients with active SLE (2007-2008)
  • Genentech WA 20500, A Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the efficacy and safety of two doses of Ocrelizumab in patients with WHO or ISN Class III or IV Nephritis due to SLE (2007-2007)
  • Wyeth, A Randomized, two arm, parallel group study of the safety, pharmacokinetics, and pharmacodynamics of TRU-015 added to standard therapy in subjects with Membranous Nephropathy secondary to Systemic Lupus Erythematosus (2010-2010)
  • BMS Lupus Nephritis IM 101-075, A sequential adaptive phase II/III multi-center, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Abatecept versus Placebo on a background of Mycophenolate Mofetil and Glucocorticoids in subjects with active Proliferative Glomerulonephritis due to Systemic Lupus Erythematosus (SLE) (2007-2011)
  • The systemic lupus erythematosus (SLE) activity gene expression (SAGE) study, XDx protocol SL 105 (2007-2008)
  • Regerneron, Phase I: A Randomized, double blind, placebo controlled, single ascending dose study of the safety and tolerability of REGN88 (IL6R-m-Ab) in subjects with Rheumatoid Arthritis receiving concomitant Methotrexate (2008-2008)
  • Boehringer Ingelheim Pramipexole Trial 248.637, Pramipexole ER in Fibromyalgia (2008-)
  • A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus patients with Active Disease. Rigel C-935788-015 (2008-2008)
  • A Randomized, Parallel, Double-blind, Placebo-controlled dose regimen finding study to evaluate the safety and efficacy of TRU-015 in Subjects with Active Seropositive Rheumatoid Arthritis on a stable background of Methotrexate, protocol 3206K1-2203-WW (2008-2011)
  • A Phase IIIB, multi-center study with a 12 week double-blind, placebo-controlled, randomized period, followed by an open-label extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis, Protocol UCB C87094. (2008-2010)
  • A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Safety Of Multiple-Dose, Intravenously Administered Medi-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis Or Polymyositis, Protocol MI-CP151. (2008-2008)
  • Medimmune MPI-CP152, A Phase IB, Multicenter, Randomized, Double-blind, Placebo-controlled, dose escalation study with an open label extension to evaluate the safety and tolerability of multiple intravenous doses of MEDI-545, a fully human Anti-Interferon-Alpha Monoclonal Antibody , in patients with Systemic Lupus Erythematosus (2007-2010)
  • Human Genome Sciences C1056, A Phase 3, Multi-Center, Randomized, Double-Blind, placebo-controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-Blys Antibody, in Subjects with SLE (2007-2010)
  • Human Genome Sciences C1066, A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-Bä), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States. (2008-2009)
  • BMS Lupus Nephritis IM 101-075, A sequential adaptive phase II/III multi-center, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Abatecept versus Placebo on a background of Mycophenolate Mofetil and Glucocorticoids in subjects with active Proliferative Glomerulonephritis due to Systemic Lupus Erythematosus (SLE) (2007-2010)
  • The systemic lupus erythematosus (SLE) activity gene expression (SAGE) sudy, XDx protocol SL 105 (2007-2009)
  • BMS IM 101-167, A Phase IIIb, Multicenter, Randomized, Withdrawal study to evaluate the Immunogenicity and safety of Subcutaneously Administered Abatacept in Adults with Active Rheumatoid Arthritis (2008-2012)
  • Amgen (AMG 827) 20070264, A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis (2009- 2010)
  • Crescendo Bioscience, Inc. CR10, Index for Rheumatoid Arthritis Measurement (InFoRM) Study (2009-2010)
  • Immune Tolerance Network: Protocol ITN034AI, A randomized, double-blind, controlled, phase II Multicenter trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis (2009-2010)
  • Array BioPharma Inc. 797-201, A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study To Investigate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Of 12 Weeks Of Treatment With ARRY-371797 In Patients With Active Ankylosing Spondylitis And Inadequate Response To Conventional Therapy (2009-2009)
  • UCB C87094, A Phase IIIB, multi-center study with a 12 week double-blind, placebo-controlled, randomized period, followed by an open-label extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis (2008-2010)
  • Roche Laboratories Inc. ML22533/A, An open-label, randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs (2009-2010)
  • Cephalon, Inc. - A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus. (2010-2011)
  • Sanofi Aventis US Inc. - A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS). Protocol Number: DRI11073 (2010-2011)
  • UCB - A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of certolizumab pegol in subjects with active axial spondyloarthritis (AS001) (2010-2011)
  • - Phase 3, multicenter, randomized, double‑blind, parallel‑group, placebo‑controlled study to evaluate the efficacy and safety of certolizumab pegol in subjects with adult‑onset active and progressive psoriatic arthritis (PsA) (2010-)
  • Duke Autoimmunity Pregnancy Registry (DAP Registry) (2010-)
  • Studies of B cell abnormalities in Systemic Lupus Erythematosus via MiRNA (2010-2011)
  • Concurrent pilot studies in Giant cell arteritis and Takayasu’s arteritis to examine the safety, efficacy, and immunologic effects of abatacept (CTLA4-Ig) in large vessel vasculitis (2010-)
  • Hp-MMP 9 levels in humans: a pilot study (2010-2011)

LECTURES AND PRESENTATIONS

 

  1. Orthopedic Grand Rounds - Biologics: A Primer for Orthopedic Surgeons. Cedars Sinai Medical Center. October 2014.
  2. Moderator for session, “Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside”. American College of Rheumatology Annual Meeting. Boston, MA. November 2014.
  3. Moderator for session, “Inflammation and Atherothrombosis.” American College of Rheumatology Annual Meeting. Boston, MA. November 2014.
  4. “Early diagnosis and treatment of Rheumatoid Arthritis”. “Hot topics in Rheumatology. The James R Klinenberg symposium. Pasadena, CA. 2014.
  5. “SLE: 2014. Update on diagnosis and treatment”. Rheumatology grand rounds. Hinduja Hospital and Research Center, Mumbai. India. 2014.
  6. “Osteoporosis: Update on diagnosis and Management”. Orthopedics research conference. Hinduja Hospital and Research Center, Mumbai, India. 2011.
  7. “Organ Manifestations of Anti-phospholipid Antibody syndrome”. Presented Grand Rounds at the Department of Medicine - Cedars Sinai Medical Center. 2010.
  8. “Inflammatory muscle disease”. Department of Medicine-Grand Rounds presentation at Cedars Sinai Medical Center. 2007.
  9. “Inflammatory muscle disease”. Department of Medicine - Grand Rounds presentation at Olive View - UCLA Medical Center.
  10. “Crystal induced arthropathies: Interactive case presentation.” James R. Klinenberg Rheumatology symposium, Cedars Sinai Medical Center, Los Angeles. 2006.
  11. “Conventional treatment of systemic extra-glandular disease in Sjogren’s syndrome”. Lecture - Sjogren’s syndrome study group. American College of Rheumatology annual meeting, San Diego, CA. November 2005.
  12. “Musculoskeletal Examination Basics”. Co-faculty for rheumatology and orthopedic housestaff. Cedars Sinai Medical Center. 2011 and 2012.
  13. “Joint injection techniques”. Lecture presentation to the Internal Medicine residency program. Cedars Sinai Medical Center, Los Angeles, CA. 2008.
  14. “Are complementary and alternative treatments effective for rheumatic diseases?” Interactive case conference. James R Klinenberg Rheumatology Symposium, Newport Beach, CA. March 2008.
  15. Rheumatoid Arthritis. Noon conference, Cedars Sinai Internal Medicine residency program. 2007.
  16. Sjogren’s syndrome. Noon conference, Cedars Sinai Internal Medicine residency program. 2007.
  17. “Joint Aspiration and Injection Training Program” At Pri-Med West, March 31 – April 2, 2005, and 2006 at the Anaheim Convention Center in Anaheim, California. 
  18. “How to perform joint injections”. Lecture/workshop presented at the James R. Klinenberg Rheumatology symposium, Cedars Sinai Medical Center, Los Angeles. 2004
  19. “Gout: an interactive case presentation”. Noon conference, Cedars Sinai Internal Medicine residency program. 2006.
  20. “Inflammatory Muscle Diseases”. Noon conference, Cedars Sinai Internal Medicine residency program. 2006.
  21. “New treatments for Rheumatoid arthritis”. A patient education seminar delivered to participants of the NIH sponsored clinical trial of tai chi versus an education seminar for rheumatoid arthritis. 2006.
  22. “Panel on future career options”; presented to American College of Physicians associate members. Southern California American College of Physicians associates conference. Westin LAX airport, Los Angeles, CA, November 15th
  23. “Case conference in Rheumatology”. Presentation made to Internal Medicine residents. A case presentation was used to discuss a rheumatological differential diagnosis and management in a woman with rash and arthritis. UCLA – San Fernando Valley Program, Sepulveda, Ca. 2002.
  24. “An introduction to Ayurvedic Medicine”. Review of the origins, diagnostic methods, and evidence for use and common herbs used in Ayurvedic medicine (traditional medicine from India) made to the UCLA - San Fernando Valley Internal Medicine Residency Program faculty and residents. Sylmar, CA. 2002.
  25. “A case of Amyloidosis presenting as SLE”. Frontiers of rheumatology conference, Newport Beach, CA 2001.
  26. Do the standards of evidence accepted by conventional medical practitioners and practitioners of complementary and alternative medicine differ? Poster presented at the sixth Annual President’s Ethics symposium. SUNY Upstate Medical University. April 1999.
  27. “Complementary and Alternative Therapies for Arthritis¾A review of the evidence.” Presentation to the department of medicine at Olive View Medical Center, Sylmar, CA.
  28. “Conducting Clinical Research in Fibromyalgia”. Presented to the Research Division, Southern California University for Health Sciences, Whittier, CA. 2001.
  29. "The Challenges of Complementary and Alternative Medicine." Senior resident Grand rounds, presented to the Chairman, faculty and residents of the Department of Medicine, SUNY Upstate Medical University, Syracuse, 1998.
  30. “Case of a 45 year old woman with hemoptysis and a lung lesion”. Clinico-Pathological Co-relation. Grand Rounds - Department of Internal Medicine - SUNY Upstate Medical University, Syracuse, NY. 1999.
  31. “Case of a 31 year old female with Hepato-splenomegaly.” Clinico-Pathological Co-relation. Grand Rounds - Department of Internal Medicine - SUNY Upstate Medical University, Syracuse, NY. 1998.
  32. “Case of a 29 year old male with dyspnea on exertion”. Clinico-Pathological Co-Relation. Grand Rounds - Department of Internal Medicine - SUNY Upstate Medical University, Syracuse, NY. 1998.
  33. “Update on the treatment of SLE”. Presentation to Center for Lupus care - a patient support group. 2011.
  34. “Complementary and Alternative Medical therapies for SLE”. Presentation to Lupus LA. June 2009.
  35. “Town Hall meeting on Rheumatoid arthritis”. Invited speaker at a town hall meeting organized by the Arthritis foundation, free event for Los Angeles county residents with rheumatoid arthritis. Co-panelists - Allan Metzger, MD and Michael Weisman, MD. 2008
  36. “Complementary and Alternative Medical therapies for SLE”. Presentation to Lupus LA. June 2008.
  37. “Medical Management of Scleroderma”. Lecture given to the Southern California Scleroderma Foundation annual meeting. 2007
  38. “Complementary and Alternative Medical therapies for SLE”. Presentation to Lupus LA. June 2007.
  39. “Town Hall meeting on Rheumatoid arthritis”. Invited speaker at a town hall meeting organized by the Arthritis foundation, free event for Los Angeles county residents with rheumatoid arthritis. Co-panelists- Allan Metzger, MD and John Klippel, M.D. 2007.
  40. “Clinical aspects of inflammatory muscle disease”. Presented to the California Myositis association annual meeting, Los Angeles, CA. 2005.
  41. “Complementary and Alternative therapies for Lupus”. A lecture/round table discussion presented at Lupus LA annual meeting - Los Angeles, CA. 2007.
  42. “New treatments for Rheumatoid arthritis”. A patient education seminar delivered to participants of the NIH sponsored clinical trial of tai chi versus an education seminar for rheumatoid arthritis. 2005.
  43. “Complementary therapies for arthritis”. A lecture given as part of “Arthritis Answers” a community based education day about arthritis organized by the Arthritis Foundation- San Fernando Valley Branch. October 16 2004.

PUBLICATIONS

RESEARCH PAPERS - PEER REVIEWED
A. RESEARCH PAPERS - PEER REVIEWED
  1. Rasmussen A, Grundahl K, Kelly JA, Venuturupalli s et al. Previous diagnosis of Sjögren’s Syndrome as rheumatoid Arthritis or Systemic Lupus Erythematosus. Rheumatology. Oxford University Press (Dec 2015)
  1. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. American College of Rheumatology. (Nov 2014)
  2. Shekelle PG, Hardy M, Morton SC, Coulter I, Venuturupalli S, Favreau J, Hilton L. “Are Ayurvedic Herbs for diabetes effective?” Journal of Family Practice, volume 54, number 10, 876-886. (2005)
  3. Venuturupalli SR, Gudsoorkar VS, Wallace, DJ. Reconsidering antimalarials in systemic lupus erythematosus: developments of translational clinical interest. J Rheumatol. 39(9):1769-71. (2012 Sept.)
  4. Wallace, DJ, Gudsoorkar VS, Weisman, MH Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 8(9):522-33. (2012 Sept)
  5. Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 65(2):314-24. doi: 10.1002/art.37754. (2013 Feb)
  6. Venuturupalli, S, Sacks, W. Review of New Guidelines for the Management of Glucocorticoid Induced Osteoporosis. Current Osteoporosis Reports. (Oct 2013)
  7. Hardy ML, Coulter ID, Shekelle PG, Favreau J, Venuturupalli S, et al. S-Adenosyl-L-Methionine for treatment of Depression, Osteoarthritis, and Liver Disease. Evidence Report/ Technology Assessment. (prepared by Southern California Evidence-Based Practice Center/ RAND under Contract No 290-97-0001.) AHRQ Publication. Rockville, MD: Agency for HealthCare Research and Quality. In press. (Sept 2002)
  8. Coulter ID, Hardy ML, Morton SC, Shekelle PG, Favreau J, Venuturupalli S et al. Mind-Body Interventions for Gastrointestinal Conditions. File Inventory, Evidence Report/Technology Assessment Number 40. AHRQ Publication No. 01-E030. Agency for Healthcare Research and Quality, Rockville, MD (July 2001)
  9. Hardy ML, Coulter ID, Venuturupalli S et al. Ayurvedic Interventions for Diabetes Mellitus: A Systematic Review. File Inventory, Evidence Report/Technology Assessment Number 41. AHRQ publication No. 01-E040. Agency for Healthcare Research and Quality, Rockville, MD. http://archive.ahrq.gov/clinic/tp/ayurvtp.htm (September 2001)
B. RESEARCH PAPERS - PEER REVIEWED (IN PRESS)
C. RESEARCH PAPERS - PEER REVIEWED (SUBMITTED)
  1. Identification of a Sjögren’s syndrome-associated variant that influences OAS1 isoform switching and protein expression. Nature Genetics. (Nov 2014)

 

RESEARCH PAPERS - NON PEER REVIEWED

  1. RESEARCH PAPERS - NON PEER REVIEWED

 

  1. Venuturupalli, RS and Wallace DJ. “Lupus Nephritis—An Update, US Renal Disease (2007); Touch Briefings, pp. 63-66, (2008.) 235
  2. RESEARCH PAPERS - NON PEER REVIEWED (IN PRESS)

  3. RESEARCH PAPERS - NON PEER REVIEWED (SUBMITTED)

                        NONE

CHAPTERS

  1. Venuturupalli S. “Fenugreek”. Book chapter in “Evidence-Based Herbal Medicine,” editors Rotblatt M, Ziment I. Philadelphia, PA, Hanley and Belfus Publ, 2001. (Oct 2001)
  2. Venuturupalli S. “Complementary and Alternative Medical Therapies for Sjogren’s syndrome”: Book chapter in “The New Sjogren’s Syndrome Handbook”. Editor Daniel J. Wallace. Oxford University Press, (2004)
  3. Wallace DJ, Venuturupalli, RS,. “Urologic manifestations of fibromyalgia”. Book chapter in “Textbook of Fibromyalgia and other non neuropathic pain syndromes”. Edited by Daniel J Wallace and Daniel J Clauw. Lippincott, Williams and Wilkins. (2005)
  4. Venuturupalli, RS, Wallace DJ. “Controversial syndromes and their relationship to fibromyalgia”. Book chapter in “Textbook of Fibromyalgia and other non neuropathic pain syndromes”. Edited by Daniel J Wallace and Daniel J Clauw. Lippincott, Williams and Wilkins. (2005)
  5. Venuturupalli, RS, Wallace DJ. “Fibromyalgia in lupus and the use of alternative therapies in lupus”. Book chapter in “Dubois’ Lupus Erythematosus”. Editors Daniel J Wallace and Bevra H Hahn. Lippincott, Williams and Wilkins. (2005)
  6. Hallegua, DH and Venurupalli, RS. “Gastrointestinal manifestations of lupus”. Book chapters in “Dubois’ Lupus Erythematosus”. Editors Daniel J Wallace, Bevra H Hahn, Michael Weisman, Ram Singh. (2005)
  7. Venuturupalli, RS and Weisman, MH. Textbook chapter: "Corticosteroids in the treatment of crystal induced arthropathies." In “Crystal induced arthropathies: gout, pseudogout and apatite-associated syndromes.” Editors Robert L Wortmann, H Ralph Schumacher, Michael Becker, Lawrence M Ryan. Taylor and Francis Books, New York, New York. (2006)
  8. Silverman, S and Venuturupalli, S. “Glucocorticoid induced Osteoporosis”. Book chapter in Osteoporosis: Diagnosis and Management, Edited by Dale Stovall. Springer (2013)
LETTERS TO THE EDITOR
  1. Venuturupalli, RS. “Evaluating Complementary medicine with the appropriate tools”. Letter to the editor BMJ, Feb 2005.
REVIEWS

      1. Peer Reviewer, Quick Essentials Emergency Medicine 1-minute Consult, 5th edition, EMresource.org

EDITORIALS
  1. Venuturupalli, RS. “Editorial” Current Rheumatology Reviews. Volume 5, Number 4, pp. 186-186(1) (November 2009)
  2. Venuturupalli, RS. “Editorial” Current Rheumatology Reviews. Volume 6, Number 1, pp. 1-1(1) (February 2010)
  3. Venuturupalli, RS. “Introduction from Editor-in-Chief.” Current Rheumatology Reviews, Volume 6, Number 2, pp. 87-87(1) (May 2010)
  4. Venuturupalli, RS. “Introduction from Editor-in-Chief.” Current Rheumatology Reviews, Volume 6, Number 3, pp. 160-161(2) (August 2010)
  5. Venuturupalli, RS. “Introduction from Editor-in-Chief.” Current Rheumatology Reviews, Volume 6, Number 4, pp 232. (November 2010)
  6. Venuturupalli, RS. “Editorial.” Current Rheumatology Reviews, Volume 7, Number 1, pp. 1 (January 2011)
  7. Venuturupalli, RS. “Editorial.” Current Rheumatology Reviews, Volume 7, Number 3, pp. 181 (August 2011)
  8. Venuturupalli, RS. “Editorial.” Current Rheumatology Reviews, Volume 7, Number 4, pp. 272 (November 2011)
  9. Ishimori, M.L., Gudsoorkar, V., Venuturupalli, S.R., Weisman, M.H.  Renal replacement therapy in lupus nephritis: Current Practice and Future Implications. Arthritis Care Res. 2011 Dec; 63(12):1639-41 (December 2011)
ABSTRACTS
  1. Rosnack D, Decker M, Venuturupalli S, Ching W. “Just CHF?”. Abstract-Journal of General Internal Medicine. Volume17, supplement 1. Pg 66. (April 2002)
  2. Venuturupalli S, Hardy M, Coulter I, Asch S, Shekelle PG. Ayurvedic treatment for diabetes – comparison of evidence available in India with evidence from Western databases. Abstract- Journal of General Internal Medicine. Volume 17, supplement 1. Pg 215 (April 2002)
  3. Hardy ML, Coulter ID, Venuturupalli S, Roth EA, Morton SC, Shekelle PG. Ayurvedic interventions for diabetes mellitus: a review of Western and Indian literature. Abstract- Journal of Herbal Pharmacotherapy. ISSN: 1522-8940 Volume 3 (1) (January 2003)
  4. Venuturupalli S, Hardy ML, Coulter ID, Roth EA, Morton SC, Shekelle PG. A method to access scientific Ayurvedic literature from India for systematic reviews. Abstract- Journal of Herbal Pharmacotherapy. ISSN: 1522-8940 Volume 3 (1) (January 2003)
  5. Wofsy, D, Askanase, A, Cagnoli, P…., Venuturupalli, S et al Treatment of Lupus Nephritis with Abatacept plus low dose pulse cyclophosphamide followed by azathioprine (the Euro-lupus regimen): Twenty four week data from a double blind controlled trial. ACR abstract #884. Annual Meeting of the American College of Rheumatology. San Diego, CA. (2013)
  6. Grewal, S, Venuturupalli, S, Ishimori, M, Weisman, M., James, J. Are Sjogren’s syndrome patients Vitamin D deficient? ACR abstract #518. Annual Meeting of the American College of Rheumatology. San Diego, CA. (2013)
  7. Ice JA, Li H, Adrianto I,… Venuturupalli S. Characterization of the Sjögren’s Syndrome Intergenic Non-Coding RNA-1. American College of Rheumatology, (November 2014)
  8. Rasmussen A, Kelly JA, Ice, J, Li, H, Venuturupalli S et al. Characterization of early and progressive autoimmunity in Sjögren’s Syndrome: the incomplete Sjögren’s Syndrome model. 13th International Symposium on Sjögren’s syndrome. Bergen, Norway. (May 2015)
  9. Rasmussen A, Grundahl K, Radfar L, Venuturupalli S et al. Previous diagnosis of Sjögren’s Syndrome as Rheumatoid Arthritis or Systemic Lupus Erythematosus. 13th International Symposium on Sjögren’s syndrome. Bergen, Norway. (May 2015)
  10. Rasmussen A, Lessard C, Adrianto I, Kelly JA, Venuturupalli S et al. Characterization of early autoimmunity in Sjögren’s Syndrome: the incomplete Sjögren’s Syndrome model. ACR abstract #49214. Annual Meeting of the American College of Rheumatology. San Francisco, CA (2015)